Minutes - May 9th, 2015


Minutes – May 9th, 2015 Meeting

The Kansas City Vasculitis Support Group met on Saturday, May 9th in room 125 Best Conference Center, University of Kansas Edwards Campus.  Present were Mary Tanner, Julie Tanner, Velda Atkinson, Marie Dalbey, Glenn & Arlene Kullman, Joyce Kullman, Judy Kullman, Shannon Morgan, Chad Gratton, Judy Harrington, Traci Marriott, Clairissa Marriott, Annette Marriott, Linda & Jim Gibson, Jude Devonshire, Tish Varraveto, Jerry & Judy Niebaum, and Denny & Ruth Hale.  Ten patients, and twelve caregivers.

Dr. Mireille El Ters, nephrologist from University of Kansas Medical Center, presented an overview of renal vasculitis.  She also discussed that she and Dr. Jason Springer were conducting a new drug (CCX168 C5a receptor inhibitor) clinical trial study for patients with renal involvement.  Dr. El Ters concluded by answering questions from the group.

Jerry Niebaum asked patient attendees to introduce themselves and provide a brief update on their vasculitis health status.

Jerry announced that after ten years he was stepping down as group leader.  Denny Hale will take over as the support group leader.

Jerry provided an overview of the Vasculitis Foundation Facebook site located at https://www.facebook.com/groups/vasculitisfoundation/

Joyce Kullman, Executive Director of the Vasculitis Foundation, announced that May is Vasculitis Awareness Month. She asked that each attendee do something to raise awareness.  Joyce thanked Tish Varraveto for conducting a tulip sale which resulted in $550 donated to the foundation.  Her other announcement was that Dr. Gary Hoffman had retired.  Dr. Hoffman of the Cleveland Clinic had been involved many years with vasculitis diagnosis, treatment, and research.

Shannon Morgan, Patient Support Co-ordinator of the Vasculitis Foundation talked about the 2015 International Vasculitis Symposium in Jacksonville, Fl. from June 19 - 21st.

The next KC Support Group meeting will be held in October, but not on the 2nd Saturday.  There are too many conflicts.  More details to follow.